Why the study?
To produce an iPSC line to help understand the pathogenic mechanism between a de novo LAMA2 heterozygous mutation and ARVC.
The establishment of this iPSC line provides a valuable in vitro cellular model to study the pathogenic mechanisms linking LAMA2 mutations to arrhythmogenic right ventricular cardiomyopathy.
Answers are grounded in this paper and cite their sources.
iPSC line models de novo LAMA2-related ARVC; leaves open mechanistic validation and therapeutic utility.
Using peripheral blood mononuclear cell (PBMC) reprogramming technology, a human-induced pluripotent stem cell (iPSC) line was produced from a patient who presents classic clinical features of arrhythmogenic right ventricular cardiomyopathy (ARVA) and carries a de novo laminin subunit alpha 2 (LAMA2) heterozygous mutation (NM_000426.3: c.8842G > A, p.G2948S). This mutation was not inherited from his parents, who also present normal cardiac phenotype. This iPSC line demonstrates a normal karyotype. Pluripotency and differentiation capacity has been confirmed in vitro. This cell line can help in efforts to understand the pathogenic mechanism between LAMA2 mutation and ARVC.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: